https://www.selleckchem.com/pr....oducts/Adriamycin.ht
Recently published studies suggested that digoxin may increase mortality in heart failure with reduced ejection fraction (HFrEF). However, in the vast majority of former trials serum digoxin concentration (SDC) was not measured and therapy was not SDC-guided. To assess the impact of SDC-guided digoxin therapy on mortality in HFrEF patients. Data of 580 HFrEF patients were retrospectively analyzed. In patients on digoxin, SDC was measured every 3 months and digoxin dosage was SDC-guided (target SDC 0.5-0.9 ng/mL). All-cause mortality
Me gusta
Comentario
Compartir
